Curis, Inc. (NASDAQ:CRIS)

CAPS Rating: 4 out of 5

A drug discovery and development company that is seeking to leverage its innovative biological signaling pathway drug technologies to create new medicines primarily in the field of cancer.

Recs

1
Player Avatar louisfool (69.59) Submitted: 10/28/2011 3:32:42 PM : Underperform Start Price: $3.72 CRIS Score: +83.49

Will underperform until approved. Look for a big pop once that happens.

Member Avatar giantwithin1 (47.16) Submitted: 1/31/2012 5:50:44 PM
Recs: 0

In November 2011, the U.S. vismodegib New Drug Application (NDA) was granted priority review by the FDA. The FDA grants priority review status to products that, if approved, would address an unmet medical need or are considered to be potentially significant therapeutic advancements over existing approved therapies in the treatment, diagnosis or prevention of a disease.

he FDA has established March 8, 2012 as the action date under the Prescription Drug User Fee Act (PDUFA) to complete its review of the NDA and potentially grant marketing approval of vismodegib.

sink or swim March 8

Featured Broker Partners


Advertisement